Market Cap 32.37M
Revenue (ttm) 0.00
Net Income (ttm) -83.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.09
Volume 92,864
Avg Vol 33,592
Day's Range N/A - N/A
Shares Out 7.31M
Stochastic %K 9%
Beta 0.58
Analysts Strong Sell
Price Target $12.50

Company Profile

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261,...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 822 5600
Address:
4000 Shoreline Court, Suite 300, South San Francisco, United States
LabPsycho
LabPsycho Jun. 13 at 2:22 PM
$KZR @youspeaktotme Don't you know that this seems to be the the goal of most biotech companies? It aint to make shareholders rich, its to sell a story, go public, original investors cash out, and management coasts along milking the coffers. 1 in 20 do okay but thats just to keep the saps coming back to biotech after being burned.
1 · Reply
DonCorleone77
DonCorleone77 May. 13 at 8:03 PM
$KZR Kezar Life Sciences reports Q1 EPS ($2.27), consensus ($2.65) Cash, cash equivalents and marketable securities totaled $114.4 million as of March 31, 2025, compared to $132.2 million as of December 31, 2024. The decrease was primarily attributable to cash used in operations. "We shared exciting results this quarter from the PORTOLA trial, the first successful randomized study in treatment-refractory AIH," said Chris Kirk, CEO and co-founder of Kezar. "There has been almost no change over the last three decades in the treatment of this serious chronic disease, and patients and physicians are in need of new and effective therapies. We are encouraged by the promising safety and efficacy data in this difficult-to-treat patient population, in particular the durable and steroid-sparing remissions observed in patients treated with zetomipzomib. We continue to respond to the FDA Division of Hepatology and Nutrition on the partial clinical hold and are working toward achieving alignment on an appropriate trial design to demonstrate the clinical benefit of zetomipzomib in AIH."
0 · Reply
youspeaktome
youspeaktome Apr. 29 at 2:01 AM
$KZR $KZR agreed. it's sad management and board are scammers
0 · Reply
gilheydari
gilheydari Apr. 29 at 12:47 AM
$KZR Maybe they will do it this time with lower price.
0 · Reply
gilheydari
gilheydari Apr. 29 at 12:44 AM
$KZR Tang still holding their position? Intersting? I think they will come with lower offer.
0 · Reply
youspeaktome
youspeaktome Apr. 27 at 4:09 PM
$KZR The reason Kezar Life Sciences is going to zero is in this chart. Management compensation for driving this company into the ground is outrageous.
2 · Reply
youspeaktome
youspeaktome Apr. 8 at 11:00 PM
1 · Reply
PharmaExpert
PharmaExpert Apr. 2 at 3:04 PM
$AKBA, $DRIO, $VERU, $KZR, $IMRN 🔥🔥🔥🔥🔥
0 · Reply
PenkeTrading
PenkeTrading Apr. 2 at 9:00 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of Kezar Life Sciences Inc. Is that bullish or bearish? $KZR #RsiOversold #NASDAQ
0 · Reply
youspeaktome
youspeaktome Mar. 27 at 10:47 AM
$KZR Down 97% over 3 years and management is still going to steal all of the remaining cash on the balance sheet. How they haven't been fired
0 · Reply
Latest News on KZR
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split

Oct 28, 2024, 8:30 AM EDT - 8 months ago

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split


Kezar Life Sciences halts mid-stage trial for lupus treatment

Sep 30, 2024, 8:46 AM EDT - 9 months ago

Kezar Life Sciences halts mid-stage trial for lupus treatment


Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023

Mar 6, 2023, 7:00 AM EST - 2 years ago

Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023


Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case

Jul 27, 2022, 1:45 PM EDT - 3 years ago

Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case


LabPsycho
LabPsycho Jun. 13 at 2:22 PM
$KZR @youspeaktotme Don't you know that this seems to be the the goal of most biotech companies? It aint to make shareholders rich, its to sell a story, go public, original investors cash out, and management coasts along milking the coffers. 1 in 20 do okay but thats just to keep the saps coming back to biotech after being burned.
1 · Reply
DonCorleone77
DonCorleone77 May. 13 at 8:03 PM
$KZR Kezar Life Sciences reports Q1 EPS ($2.27), consensus ($2.65) Cash, cash equivalents and marketable securities totaled $114.4 million as of March 31, 2025, compared to $132.2 million as of December 31, 2024. The decrease was primarily attributable to cash used in operations. "We shared exciting results this quarter from the PORTOLA trial, the first successful randomized study in treatment-refractory AIH," said Chris Kirk, CEO and co-founder of Kezar. "There has been almost no change over the last three decades in the treatment of this serious chronic disease, and patients and physicians are in need of new and effective therapies. We are encouraged by the promising safety and efficacy data in this difficult-to-treat patient population, in particular the durable and steroid-sparing remissions observed in patients treated with zetomipzomib. We continue to respond to the FDA Division of Hepatology and Nutrition on the partial clinical hold and are working toward achieving alignment on an appropriate trial design to demonstrate the clinical benefit of zetomipzomib in AIH."
0 · Reply
youspeaktome
youspeaktome Apr. 29 at 2:01 AM
$KZR $KZR agreed. it's sad management and board are scammers
0 · Reply
gilheydari
gilheydari Apr. 29 at 12:47 AM
$KZR Maybe they will do it this time with lower price.
0 · Reply
gilheydari
gilheydari Apr. 29 at 12:44 AM
$KZR Tang still holding their position? Intersting? I think they will come with lower offer.
0 · Reply
youspeaktome
youspeaktome Apr. 27 at 4:09 PM
$KZR The reason Kezar Life Sciences is going to zero is in this chart. Management compensation for driving this company into the ground is outrageous.
2 · Reply
youspeaktome
youspeaktome Apr. 8 at 11:00 PM
1 · Reply
PharmaExpert
PharmaExpert Apr. 2 at 3:04 PM
$AKBA, $DRIO, $VERU, $KZR, $IMRN 🔥🔥🔥🔥🔥
0 · Reply
PenkeTrading
PenkeTrading Apr. 2 at 9:00 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of Kezar Life Sciences Inc. Is that bullish or bearish? $KZR #RsiOversold #NASDAQ
0 · Reply
youspeaktome
youspeaktome Mar. 27 at 10:47 AM
$KZR Down 97% over 3 years and management is still going to steal all of the remaining cash on the balance sheet. How they haven't been fired
0 · Reply
frontiere
frontiere Mar. 26 at 8:01 PM
$KZR Kezar ref=$5.05 — goes into our “Avoid” pile after they spurned Tang’s buyout offer — mgmt showing they are not going to do what’s best for outside shareholders — cash >110m as of 2024-12-31 MCap now down <$40M but Portola Ph2 readout this week flimsy, took 2yrs w 24 pts now Ph3 will need its own funding. Rare Neg EV biotech in a full avoid pile no matter the price.
1 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 26 at 6:49 AM
$KZR Tough week for KZR. PALIZADE trial halt is brutal. Pivoting focus to PORTOLA AIH trial - hoping for better data in H1 2025. Biotech's a rollercoaster. Watching closely but not jumping in yet. good article: https://beyondspx.com/article/kezar-life-sciences-kzr-navigating-the-uncertain-terrain-of-autoimmune-diseases
0 · Reply
gilheydari
gilheydari Mar. 25 at 4:51 PM
$KZR what is wrong here? Results was not good?
0 · Reply
gilheydari
gilheydari Mar. 25 at 2:01 PM
$KZR big drop low volume, I see
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Mar. 25 at 11:56 AM
$KZR Kezar Life Sciences Q4 2024 GAAP EPS $(2.77) Beats $(2.88) Estimate, Cash $132M
0 · Reply
DonCorleone77
DonCorleone77 Mar. 25 at 11:51 AM
$KZR Kezar Life Sciences reports topline results from PORTOLA trial Kezar Life Sciences reported topline results from the PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a selective immunoproteasome inhibitor, in patients with autoimmune hepatitis and reported fourth quarter and year end 2024 financial results. The primary efficacy endpoint of PORTOLA, which was not powered for efficacy, evaluated the proportion of patients who achieved a CR by Week 24, measured as normalization of alanine aminotransferase, aspartate aminotransferase and Immunoglobulin G values, with steroid dose levels not higher than baseline. A key secondary endpoint was the proportion of patients who achieved a CR by Week 24 with a steroid dose of 5 mg/day or less. The PORTOLA trial included a pre-specified subgroup analysis of patients who were on steroid-based therapy at the time of screening, which represents a patient population with unmet medical needs for a potential future registrational study. Additional exploratory endpoints included changes in histologic assessment of AIH as measured in biopsies taken within six months of screening and repeated at Week 24 of the trial. PORTOLA enrolled 24 patients as the ITT population. Consistent with the AASLD treatment goals, zetomipzomib treatment resulted in higher rates of complete biochemical responses combined with reduction of steroid dosage to 5 mg/day or less, compared to placebo. In the ITT population: without regard to steroid taper, 50.0% of zetomipzomib patients achieved a CR, compared to 37.5% of placebo patients; 31.3% of zetomipzomib patients achieved both a CR and steroid taper to 5 mg/day or less, compared to 12.5% of placebo patients; 18.8% of zetomipzomib patients achieved both a CR and complete steroid withdrawal to zero mg/day, compared to 0% of placebo patients; median duration of response in zetomipzomib patients achieving a CR was 27.6 weeks, and no disease flares were reported in any zetomipzomib-treated patient achieving CR. Disease flares were defined as a sustained increase in ALT values to 25% above the CR value or 1.25-fold higher than the upper limit of normal for more than one week and requiring a restart or increase in steroid dose. In the pre-specified subgroup analysis, 21 of the 24 patients entered the study on a steroid-based therapy at the time of screening. One patient in the placebo arm and two patients in the zetomipzomib arm were not receiving steroids at screening. All patients on study were required to initiate treatment with an initial prednisone dose of 20-40 mg/day. Of the 21 patients in this subgroup analysis: median steroid use at screening was 20 mg/day for patients enrolled in the zetomipzomib arm, compared to 10 mg/day in the placebo arm, indicating that the zetomipzomib-treated arm was more refractory than the placebo arm; without regard to steroid taper, 57.1% of zetomipzomib patients achieved a CR, compared to 28.6% of placebo patients; 35.7% of patients on the zetomipzomib arm achieved a CR and steroid taper to 5 mg/day or less, compared to 0% of placebo patients; 21.4% of patients on the zetomipzomib arm achieved a CR and complete steroid withdrawal to zero mg/day, compared to 0% of placebo patients. Treatment-emergent adverse events were seen in all patients, with injection site reactions being the most commonly reported TEAE in both arms. Systemic injection reactions, with onset occurring 8 to 24 hours post-dose and usually resolving within 48 hours, were all Grade 1 and Grade 2. SIRs are a protocol-defined set of specific adverse events consisting of one or more of the following signs/symptoms: hypotension, tachycardia, nausea, vomiting, dizziness, headache, pyrexia, rigors and/or chills. Three patients experienced treatment-emergent serious adverse events: one in the placebo arm, a Grade 3 variceal bleeding with hematemesis and atrial fibrillation; and two in the zetomipzomib arm, a Grade 3 fever occurring after the Week 24 liver biopsy, and a Grade 3 influenza infection that fully resolved during study. All SAEs were considered unrelated to study treatment, and all three patients completed the double-blind treatment period. Infectious AEs were reported in 85.7% of patients in the placebo arm and 56.3% of patients in the zetomipzomib arm. One patient discontinued from the placebo arm for a UTI requiring antibiotic treatment prior to receiving a dose on study, and three patients discontinued on the zetomipzomib arm for a Grade 1 fatigue, Grade 2 hives and a Grade 2 AIH disease flare. The safety population includes all patients who received at least one dose of study treatment.
0 · Reply
RAPIDTRADX
RAPIDTRADX Mar. 25 at 11:08 AM
$KZR KEEP 👀 ON
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Mar. 25 at 10:44 AM
WATCHLIST MAR 25 2025. $KZR Kezar Life Sciences To Present Topline Results From The Portola Phase 2a Trial Evaluating Zetomipzomib For The Treatment Of Patients With Autoimmune Hepatitis On Tuesday, March 25, 2025 $PLUG HC Wainwright & Co. Reiterates Buy on Plug Power, Maintains $3 Price Target $KBH KB Home Appoints Robert R Dillard As Executive Vice President And Chief Financial Officer, Effective March 31, 2025 $GRO Brazil Potash shares are trading higher after the company announced it signed a key vegetation management contract for site preparation at its Autazes Potash project in Amazonas state. $CVM CEL-SCI Announces Publication From Prior 3 Study Of Multikine In Journal 'Pathology and Oncology Research'
0 · Reply
powersofcompound
powersofcompound Mar. 24 at 2:29 PM
$KZR way under cash. topline ph2 tmrw. AIH is large market with unmet need. Has activist bidder. A very nice setup. $GME $RDDT $OKLO
1 · Reply
TwongStocks
TwongStocks Mar. 24 at 12:28 PM
$KZR Topline results from PORTOLA Phase 2a trial to be presented Mar 25. Conference call at 8am ET. https://ir.kezarlifesciences.com/news-releases/news-release-details/kezar-life-sciences-present-topline-results-portola-phase-2a
0 · Reply
riskytwits
riskytwits Mar. 14 at 6:58 PM
$KZR this mfa has not move in like a year. The f is going on
0 · Reply
powersofcompound
powersofcompound Feb. 21 at 12:01 PM
$KZR Key Opinion Leader event (KOL) on the 27th Feb. Looks like their AIH ph2 asset is gold. This should be repriced. No cash worries, big market in AIH. $XBI
0 · Reply